title: Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin.
abstract: Bullous pemphigoid is an autoimmune subepidermal blistering disorder that typically affects elderly adults but can also occur in childhood. We report on a 3-month-old boy who developed bullous pemphigoid 1 week after the second routine administration of a hexavalent vaccine. The disease was resistant to standard therapies (including oral and topical corticosteroids) but was relieved by intravenous immunoglobulin treatment. There was no recurrence of bullous pemphigoid after the next vaccination (3 mos after discontinuation of steroids).
authors.affiliation: Department of Pediatrics, Victor Provo Hospital, Roubaix, France.
authors.forename: Marielle
authors.initials: M
authors.lastname: Ister
authors.forename: Guillaume
authors.initials: G
authors.lastname: Pouessel
authors.forename: Hubert
authors.initials: H
authors.lastname: Ythier
authors.forename: Benoit
authors.initials: B
authors.lastname: Catteau
authors.forename: Olivier
authors.initials: O
authors.lastname: Carpentier
mesh_terms: D001623:Betamethasone / Q000627:therapeutic use; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000009:adverse effects*; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005076:Exanthema; D005938:Glucocorticoids / Q000627:therapeutic use*; D017325:Hepatitis B Vaccines / Q000009:adverse effects*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007223:Infant; D008297:Male; D010391:Pemphigoid, Bullous / Q000188:drug therapy / Q000209:etiology*; D011054:Poliovirus Vaccine, Inactivated / Q000009:adverse effects*; D011239:Prednisolone / Q000627:therapeutic use
chemical_list: D015721:Diphtheria-Tetanus-Pertussis Vaccine; D005938:Glucocorticoids; D017325:Hepatitis B Vaccines; C426944:Hexavac; D016756:Immunoglobulins, Intravenous; D011054:Poliovirus Vaccine, Inactivated; D001623:Betamethasone; D011239:Prednisolone